Beclin-1 was known for its ability to affect the sensitivity of cancer to targeted therapy such as gefitinib, osimertinib and sorafenib [18–20], but was not involved in autophagy-dependent resistance to erlotinib in tongue squamous carcinoma [21]. Here, BECN1 is linked to cancer.